The purpose of this study is to find out if one year of romosozumab (Evenity®), a monthly
injection given in the arm under the skin, prior to an infusion of zoledronic acid Reclast®,
works to treat bone loss and prevent it from worsening in older women (ages 65 and older) who
have osteoporosis and reside in long-term care (LTC) facilities.
Phase:
Phase 4
Details
Lead Sponsor:
Susan L. Greenspan
Collaborators:
National Institute on Aging (NIA) National Institutes of Health (NIH)